Express News | RenovoRx Regains Nasdaq Compliance

Moomoo 24/7Apr 18 08:35 ET

Express News | RenovoRx Regains Compliance With Nasdaq Stockholders’ Equity Requirement

Moomoo 24/7Apr 18 08:30 ET

RenovoRx Regains Compliance With Nasdaq Stockholders' Equity Requirement

Shaun Bagai, Chief Executive Officer of RenovoRx, stated, "Regaining compliance with Nasdaq's listing requirements represents another critical achievement for RenovoRx.

Business WireApr 18 08:30 ET

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

Sub-study of the pivotal Phase III TIGeR-PaC clinical trial offers important data to potentially assist in optimization of TAMP therapy.

Business WireApr 16 08:30 ET

Express News | RenovoRx Inc : Alliance Global Partners Cuts Target Price to $3.5 From $4

Moomoo 24/7Apr 15 10:34 ET

RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway Into 2026

RenovoRx, Inc. ("RenovoRx" or the "Company") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the closing of its previously announced private placement of approximately $11.1 million in gross proceeds.

BusinesswireApr 15 08:00 ET